Pregabalin Vs. Opioids for the Treatment of Neuropathic Cancer Pain: A Prospective, Head-to-Head, Randomized, Open-Label Study
| Autor: | Athina Vadalouca, Eriphili Argyra, Ioanna Siafaka, Efklidis Raptis, Evmorfia Stavropoulou, Aikaterini Melemeni |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_treatment Pregabalin Fentanyl Patient satisfaction Neoplasms Humans Medicine Prospective Studies Adverse effect gamma-Aminobutyric Acid Aged Pain Measurement business.industry Middle Aged Analgesics Opioid Treatment Outcome Anesthesiology and Pain Medicine Opioid Anesthesia Neuropathic pain Neuralgia Female business Cancer pain Adjuvant medicine.drug |
| Zdroj: | Pain Practice. 14:32-42 |
| ISSN: | 1530-7085 |
| Popis: | Objectives Neuropathic cancer pain (NCP) is a common manifestation of cancer and/or its treatment. Treatment following the WHO analgesic ladder provides relief for the majority of cancer pain patients; however, concern remains that opioids may be less efficacious for neuropathic pain (NP) compared with nociceptive pain, often necessitating the use of higher doses. Adjuvants, such as pregabalin, have shown to be efficacious for the treatment of NP, although data come mostly from noncancer studies. The comparative efficacy and safety of opioids versus adjuvants has not been studied for NCP. The aim of this study was to directly compare pregabalin versus a strong opioid for the treatment of NCP. Methods A total of 120 patients, diagnosed with “definite” NCP, were randomized into two groups and received increasing doses of either oral pregabalin or transdermal fentanyl for 28 days. VAS score, patient satisfaction, need for opioid rescue, and adverse events (AEs) were recorded. Results In the pregabalin group, a significantly higher proportion of patients achieved at least 30% reduction in VAS compared with the fentanyl group (73.3%, 95% CI: 60.3%–83.93 vs. 36.7%, 95% CI: 24.5%–50.1%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text